COX-2 Sales Reps Remain "Extraordinarily Busy" At Pfizer
This article was originally published in The Pink Sheet Daily
Executive Summary
Celebrex and Bextra had strong fourth quarter sales despite Merck's withdrawal of Vioxx, CEO McKinnell says. Pfizer will hold off on deciding whether to restructure its COX-2 inhibitor team until after an FDA advisory committee review next month.